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Guillain–Barré and another had severe thrombocytopenia. 
Four patients had underlying illness. One of the reported 
cases was pregnant. Three of 13 patients tested had a weak-
positive result for dengue IgM. The majority of patients 
were born in Suriname and/or visiting friends and relatives 
(VFR).
Conclusions Providing pre-travel advice among travellers, 
especially VFR travellers, is needed to enhance the use of 
preventive measures against ZIKV infection. Further evi-
dence on health risks associated with ZIKV infection is 
urgently needed.
Keywords Imported viral diseases · Netherlands · Zika 
virus · Travel · Surinam · Dominican Republic
Introduction
Zika virus (ZIKV) is a flavivirus transmitted by Aedes mos-
quitoes which has recently emerged in South and Central 
America, causing large numbers of human infections. After 
discovery of the virus in 1947 in Uganda, serological evi-
dence of virus circulation has been reported from various 
African and Asian countries. However, up to 2007, ZIKV 
was not associated with epidemics. To date, two lineages of 
ZIKV are known, an African and an Asian lineage. The latter 
caused the first outbreak of ZIKV on Yap Island and adjoin-
ing islands in the Federate State of Micronesia in 2007 [1]. 
Subsequently, outbreaks occurred in French Polynesia, New 
Caledonia, the Cook Islands and Easter Island, before ZIKV 
was first noticed in Brazil in May 2015 [2]. Currently, ZIKV 
infections have been reported from a large number of South 
American countries and territories, including several Car-
ibbean islands [3]. In Surinam, a country in South America 
bordering northern Brazil, the first case was confirmed in 
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Methods In a multi-centre study, we collected epidemio-
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Results Most cases had a self-limiting course of dis-
ease, two patients developed complications, one had 
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November 2015 [2]. In the three Dutch Caribbean municipal-
ities, the first case of endemic ZIKV infection was reported 
from Bonaire, on February 15. As of March 8, no endemic 
cases have been reported from the other two Dutch Caribbean 
municipalities (Sint Eustatius and Saba). However, the three 
Dutch overseas territories (Curacao, St. Maarten and Aruba) 
have reported multiple autochthonous cases [3].
About 80 % of ZIKV infections remain asymptomatic; 
symptoms are generally mild and include a maculopapu-
lar rash, fever, headache and conjunctivitis [2]. Since late 
2015, there are increasing concerns about the probable 
association between ZIKV infection and the development 
of congenital malformations. In Brazil, the reported preva-
lence of newborns with microcephaly increased sharply 
since the start of the outbreak in May 2015 [4]. Several 
case reports of congenital malformations where ZIKV 
has been detected have been published [4, 5]. An addi-
tional concern is the increase in Guillain–Barré syndrome 
(GBS) which has been reported in multiple affected coun-
tries including Brazil and Ecuador among people recently 
infected with ZIKV [4]. Recently, a case–control study in 
Polynesia found a strong association between ZIKV infec-
tion and GBS, suggestive of a causal relation [6]. Apart 
from the main mode of transmission by mosquitoes, there 
is evidence of other routes of transmission such as sexual 
transmission through blood transfusion [4]. The possibility 
of transmission via urine and saliva remains unclear.
On the 1st of February 2016, the WHO declared the recent 
clusters of microcephaly and neurological disorders and their 
possible association with ZIKV (in the Americas) to be a Pub-
lic Health Emergency of International Concern (PHEIC). In 
this declaration, countries are requested to share clinical, viro-
logical and epidemiological data regarding microcephaly inci-
dence, neurological disorders and ZIKV transmission with the 
WHO, to facilitate sharing of knowledge, guide future actions 
for control efforts and research on an international level [7]. 
Along with the spread of the virus in the Americas, there is an 
increasing risk of introduction of ZIKV into Europe as there is 
intense travel activity between Europe and the affected coun-
tries. Introduction of ZIKV into Europe by travellers from the 
Americas has been described in Italy and France in 2015 and 
2016. These were all cases of self-limiting illness [8, 9]. In this 
rapid communication, we describe epidemiological, virologi-
cal and clinical characteristics of 18 reported ZIKV infection 
cases in the Netherlands. Seven of the earliest cases have been 
briefly described elsewhere before a standardised comprehen-
sive nation-wide registry became functional [10–12].
Methods
ZIKV infection is currently not mandatory notifiable in 
the Netherlands. Cases are defined by a ZIKV-positive 
quantitative real-time polymerase chain reaction (qRT-
PCR) test result in an individual with symptoms. Addi-
tional data on travel history, underlying illnesses, use of 
precautions to avoid mosquito bites, clinical symptoms, 
laboratory results, complications and pregnancy were col-
lected through the cases’ physicians using a standardised 
form. No information was asked about sexual history of the 
patients in the period before onset of symptoms.
Results
An overview of clinical and epidemiological data from 
the 18 cases is presented in Table 1. The mean patient age 
was 49 years (range 8–61, median 54 years), 12 cases were 
female. Of the 15 patients with reported country of birth, 
nine were born in the Netherlands and six in Surinam. 
One of the cases was reported to be pregnant; this preg-
nancy ended in an intrauterine foetal death. All cases were 
symptomatic with rash being most frequently observed 
(17 cases), followed by fever (16 cases) and arthralgia 
(13 cases). Rash was either confined to certain body parts 
or spread over the entire body, in 11 cases the rash was 
accompanied with itch. One case developed GBS, which 
may have been the result of ZIKV infection. Severe and 
persistent thrombocytopenia with bleeding complications, 
possibly immune mediated, was observed in one female 
patient, which is described in detail elsewhere [12]. All 18 
subjects resided in the European part of The Netherlands. 
In total, 17 had travelled to Surinam during the period 
of most likely acquisition of the ZIKV infection and one 
travelled to the Dominican Republic. Travel destinations 
in Surinam were predominantly the northern districts, and 
included cities (mainly Paramaribo) as well as rural areas, 
including some resorts and nature reservations. The pur-
pose of travel was visiting friends and relatives (VFR) for 
nine cases, holiday for eight cases, and work related for one 
case. Six cases had used DEET-based mosquito repellent. 
Six cases had obtained travel advice regarding personal 
protection against mosquito bites.
Onset of symptoms was abroad, on the day of return to 
the Netherlands and after return to the Netherlands (range 
1–7 days) for four, six and eight cases, respectively. Labora-
tory confirmation of one case was performed in Surinam, by 
qRT-PCR. The period between onset of symptoms and labo-
ratory confirmation ranged from 1 to 9 days, with a mean 
of 4 days. Underlying illness was reported in four patients 
and included a history of breast cancer, diabetes, hyperten-
sion and multiple sclerosis. Laboratory results for chikun-
gunya virus, either qRT-PCR or serology, were available in 
12 patients and were all negative. Dengue virus laboratory 
results were available in 13 cases (11 patients with both anti-
body test and nonstructural protein 1 (NS1) antigen test, two 
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with only NS1 antigen test). Of these, four patients were 
dengue IgG positive (of which one equivocal), and three 
were weakly IgM positive. Eight patients were known to 
have been vaccinated against yellow fever. Blood abnormali-
ties were found in all cases; (discrete) leucopenia as well as 
elevated liver enzymes was observed in five cases. Time to 
resolution was known for most patients, ranging from 2 days 
to 8 weeks, and it depended on severity of symptoms.
Discussion and conclusion
We report 18 cases of ZIKV infections imported into the 
Netherlands. Most cases had a self-limiting course of dis-
ease, with the exception of a patient with GBS and a patient 
with thrombocytopenia and subcutaneous bleedings. Under-
lying illness was reported for the GBS case. The NS1 anti-
gen test, which is a useful tool for detection of acute dengue 
infections, was negative in all 13 cases tested for dengue. 
Among the 13 cases tested for dengue, only three had a 
weak-positive dengue IgM result. Cross-reactivity of anti-
bodies against other flaviviruses mainly with dengue virus 
infection has been well documented [13]. Several patients 
had elevated liver enzymes suggesting involvement of the 
liver by the ZIKV infection, which is also frequently seen in 
dengue virus infections [14]. Information about the sexual 
history of the patients in the period before onset of symp-
toms was not ascertained in this study. Seventeen cases 
were imported from Surinam, consistent with the high 
rate of transmission reported there [3]. Due to historic ties 
between the countries, travel to Surinam from the Nether-
lands is relatively frequent and the duration of stay is com-
paratively long. These ties also exist for the Dutch Carib-
bean; however, during the Christmas holidays when travel 
was frequent, there was no evidence of ZIKV in these areas 
yet. Kramer et al. (2008) found that 60 % (1159/1938) of 
migrants from Surinam and the Dutch overseas territories, 
participating in their study and residing in the Netherlands, 
had travelled to their country of origin during the preceding 
5 years [15]. The majority of patients described (11 of 16 
with information) was visiting friends and relatives (VFR) 
and/or were born in Surinam. International studies suggest 
that VFR travellers experience a higher risk of contracting 
travel-related infectious diseases compared to other groups 
of international travellers. VFR travellers are less likely to 
obtain pre-travel medical advice, usually have closer contact 
with local populations and their associated housing condi-
tions, and are more likely to have a longer duration of travel 
[16, 17]. Several other European countries have reported 
importation of ZIKV infection cases [8, 9]. A number of 
cases had used DEET-based mosquito repellents. Whether 
infection in these cases was caused by improper use of the 
repellent or ineffectiveness of the repellent itself, could 
not be determined. Local transmission of ZIKV is consid-
ered unlikely in the Netherlands due to suboptimal climate 
conditions and lack of establishment of the major ZIKV 
vector Ae. aegypti and the potential vector Ae. albopictus 
[18]. However, incidental transmission of ZIKV by sexual 
transmission could be possible. Given the presence of Ae. 
aegypti and Ae. albopictus in other parts of Europe and the 
past outbreaks of chikungunya and dengue in various Euro-
pean countries, small outbreaks of ZIKV infections cannot 
be excluded in these areas in the future [19].
The emergence of ZIKV in South and Central America, 
the possible association with birth defects and neurological 
conditions, and the PHEIC statement of the WHO requires 
a comprehensive and fast public health response. Glob-
ally, the key research priority is to establish whether ZIKV 
has a causal relation with the occurrence of birth defects 
and neurological complications. Additionally, the possible 
sexual transmission of ZIKV as described in various case 
reports requires further research and diagnostic evidence to 
determine the probability of this transmission route [20]. 
In the Netherlands, multiple interventions in terms of pre-
paredness, prevention and control of ZIKV infections are 
being implemented. These involve development of guide-
lines for testing of pregnant women with exposure to ZIKV 
in endemic areas during gestation, and guidelines for fol-
low-up and clinical management of cases with abnormali-
ties during pregnancy. Mosquito control activities in the 
Dutch overseas territories are ongoing. From a microbio-
logic perspective, diagnostics and testing algorithms need 
to be improved by determining the kinetics of ZIKV in 
clinical samples, and the development of a ZIKV-specific 
serological assay to identify current and past infections and 
distinguish these from other flavivirus infections. Other 
challenges include the optimal surveillance of ZIKV infec-
tions and their possible complications as well as providing 
information about the current global ZIKV situation and 
the need for pre-travel advice to the general public espe-
cially pregnant women and women intending to become 
pregnant (www.rivm.nl). Increasing pre-travel awareness of 
infectious diseases among travellers, especially VFR travel-
lers, might enhance use of personal protection against mos-
quito bites (clothing, bed nets, and mosquito repellents).
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Dutch ZIKV study team: Academic Medical Center, Uni-
versity of Amsterdam: A Goorhuis, MP Grobusch, J Schin-
kel; Erasmus Medical Center, Rotterdam: AA van der Eijk, 
MP Koopmans, SD Pas, CB Reusken; Harbour Hospital, 
Rotterdam: PJJ van Genderen; M de Mendonça Melo; 
Leiden University Medical Centre, Leiden: LG Visser; 
National Institute for Public Health and the Environment, 
Bilthoven: MAH Braks, JT van Dissel, JW Duijster, SJM 
Hahné, JHTC van den Kerkhof, JL Murk (also: University 
Medical Center, Utrecht), JH Reimerink, B Rockx, MA van 
der Sande, I Schreuder, CM Swaan, A Timen, MJ te Wierik.
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